3.1. Lipophilic functional compounds
The food, pharmaceutical, cosmetic and medical industries need to deliver a range of lipophilic functional components, including bioactive lipids, nutraceuticals, therapeutic agents, and drugs. However, many of these compounds are prone to degradation and crystallization upon exposure to environmental conditions, poor water solubility, unpleasant odor, and low bioavailability [
11,
58,
59]. Emulsion-based delivery systems have been reported to overcome most of these drawbacks, including the improvement in their solubility and chemical stability [
60,
61,
62].
The single oil-in-water (O/W) emulsions are the simplest delivery systems for encapsulating lipophilic functional compounds. These systems ensure protection and target delivery by dispersing oil droplets containing the lipophilic compound in an aqueous phase containing an emulsifier or surfactant [
55,
63,
64]. Emulsifiers are amphiphilic molecules that act at the oil-water interface reducing the tension between the phases, favoring the droplet breakup and preventing the recoalescence of the droplets during the emulsification process [
65]. The type and concentration of the emulsifiers, as well as the droplet size polydispersity, are the main factors that govern the kinetic stability of these systems against the main destabilization mechanisms (i.e., flocculation, coalescence, creaming, and Ostwald ripening) [
11]. There are a significant number of emulsifiers classified as food-grade ingredients, including low molecular weight surfactants (polyoxyethylene sorbitan fatty acid esters (Tweens), polyglycerol polyricinoleate (PGPR), and sorbitan fatty acid esters (Spans)), phospholipids (soybean lecithin), and biopolymers (proteins and carbohydrates) [
63,
66].
Khalid et al., (2016) [
42] investigated the effects of emulsifier type, bovine serum albumin (BSA) and polyoxyethylene (20) sorbitan monolaurate (Tween 20) on droplet formation characteristics and stability of emulsions encapsulating quercetin produced in straight-through microfluidic devices. Both emulsifying molecules have non-attractive interaction with the chip surface; thus, uniform-sized droplets could be generated regardless of the type of emulsifier. However, more stable droplet generation and smaller droplet size were observed with Tween 20 (nonionic emulsifier) in comparison to BSA (protein emulsifier). After optimizing microfluidic process parameters (
Jd = 20 L/m
2 h
1 and
Qc = 250 ml/h) and ingredient formulations (1% w/w Tween 20 and 0.4 mg/ml quercetin in MCT oil), the delivery systems showed encapsulation efficiency superior to conventional emulsification methods, exceeding 70% after 30 days of storage at 4 and 25 °C. In a similar study, Khalid, Shu, et al., (2017) [
39] showed that the purity of the lipophilic compound could also influence the droplet generation process in straight-through microfluidic devices. Typically, low-purity commercial compounds have stabilizing ingredients that disfavor emulsification. In these cases, optimized process conditions and suitable emulsifiers are key factors for successful encapsulation. Different emulsifiers (1% w/w sodium dodecyl sulfate (SDS), decaglycerol monooleate (MO-7S), decaglycerol monolaurate (ML-750), modified lecithin (ML), and sodium caseinate (Na-Cs)) with different stabilizing mechanisms were used to stabilize O/W emulsions encapsulating astaxanthin (AXT) extracts in two purity degree, Zanthin® (ZA, purity 10%) and AstaReal® (AR, purity 20%). All emulsifiers, except Na-Cs, promoted the production of uniform droplets of MCT oil with ZA extract into the microchannels. The same behavior was observed during the generation of oil droplets with AR extract stabilized by polyglycerol fatty acid esters (ML-750 and MO-7S) and the ionic emulsifier (SDS). In contrast, broad size distribution curves confirmed the unstable generation of oil droplets with AR extract stabilized by protein-based emulsifiers (Na-Cs and ML). These results showed that the chemical composition of the lipophilic compound could directly affect the ability of the emulsifier to reduce the interfacial tension between the oil-water phases, which may or may not favor the process of forming stable droplets in straight-through microfluidic devices.
Straight-through microfluidic devices were also used to assess the effect of different concentrations of two different lipophilic compounds, γ-oz and β-st, on droplet formation characteristics of emulsions [
42]. At low concentrations (0.5 - 1% (w/w) each) of γ-oz and β-st and
Qd between 1–5 mL/h, small droplets (diameters between 26.5 and 28.5 μm) could be formed uniformly with no signal of wetting by the dispersed phase on the chip surfaces. Besides, very small Ca numbers (1.0×10
−3 - 1.4×10
−3) indicated a smooth droplet generation into microchannels without the influence of different flow rates on the droplet size. On the other hand, at high concentrations γ-oz and β-st (1.0 - 4% (w/w) each), an increase in droplet size and polydispersity was observed, which may be associated with the crystallization of the lipophilic compounds in the dispersed phase. The emulsions formulated with γ-oz and β-st (1% w/w Tween 20 and
Qd = 2 mL/h) maintained the encapsulation efficiency of more than 80% during 30 days of storage period at room and refrigerated temperatures. Besides, the γ-oz and β-st retention values in O/W emulsions (14 μg/mL and 53 μg/mL, respectively) correlated well with the recommended daily intake values.
In a more recent study, fucoxanthin's chemical stability and bioaccessibility during
in vitro digestion of O/W emulsions produced by straight-through microchannel emulsification and high-pressure homogenization were compared [
40]. The chemical stability of fucoxanthin in emulsions produced by microfluidics was significantly higher than those produced by high-pressure homogenization. In contrast, the free fatty acids released and fucoxanthin bioaccessibility in emulsions using microfluidics (around 10%) were significantly lower than using a high-pressure homogenizer (around 60%). The high-energy emulsification process caused degradation of fucoxanthin but led to significantly smaller droplet generation than microfluidics (0.14 μm and 33.7 μm, respectively). Large oil droplets reduced the number of triacylglycerol molecules exposed to the lipase action; thus, only a small amount of fucoxanthin could be released from emulsions produced by straight-through microchannel emulsification.
As lipid digestion is an interfacial process, the oil droplet size and the nature of carrier ingredients play an important role in the lipid hydrolysis (lipolysis) rate of O/W emulsions [
63,
67,
68]. Most food-grade emulsions are produced with medium-chain triglycerides (MCT) or long-chain triglycerides (LCT), such as soybean oil, rapeseed oil, and sunflower oil [
40,
41,
69,
70]. The LCT oil is formed by unsaturated fatty acids, which makes its molecular structure more complex and bent, whereas the MCT oil is saturated with a linear molecular structure [
64]. These structural differences affect the hydrophobicity, solubility of the lipophilic compound, and lipolysis rate of O/W emulsions during digestion. In general, long-chain free fatty acids accumulate at the oil-in-water interface, while medium-chain ones tend to move towards the aqueous phase due to their lower hydrophobicity [
71]. Thus, LCT systems offer lipophilic compounds higher bioaccessibility and protection during digestion than MCT systems [
64]. Furthermore, considering that many lipophilic compounds must be absorbed in the intestine to promote health benefits, they must pass the gastric digestion step intact, resisting the stomach acid pH [
72]. Some gelling biopolymers, such as gelatin, alginate, kappa-carrageenan, and pectin, are resistant to gastric conditions and can protect the bioactive until it reaches the small intestine to be absorbed [
28,
72,
73,
74]. These biopolymers can form three-dimensional (3D) networks composed of crosslinked hydrophilic chains that allow the encapsulation of hydrophilic compounds. The encapsulation of lipophilic compounds can be accomplished by creating a core surrounded by the polymer matrix [
43], which makes emulsions ideal templates for obtaining these systems. (J. Zhang, Zhang, et al., 2021) [
75] designed a simple method to prepare O/W emulsion encapsulating vitamin A using a microscale 3D printed microfluidic device. Sodium alginate, gelatin, and ethylenediaminetetraacetic acid calcium disodium salt hydrate (EDTA-Ca) were used as the continuous phase, while vitamin A mixed with tert-butyl hydroquinone (ratio of 4:1) were used as dispersed phase. The emulsion droplets were collected in an acid environment similar to the gastric fluid to generate microgels since the acid caused calcium ions (Ca
2+) leakage from the EDTA-Ca and crosslinking with sodium alginate. The low vitamin A concentration in the simulated gastric fluid (about 20%) indicated that the microgels were stable, preventing the release of bioactive. However, the polymeric matrix of the microgels was destroyed in simulated intestinal fluid, allowing the release of vitamin A (around 75%) within 2.5 h.
Unlike highly hydrophilic biopolymers, synthetic polymers can be built from different monomers that, depending on original features and proportions in the polymer chain, define the chemical and physical properties of the synthesized material [
76]. Some synthetic polymers have already been classified as food-grade, such as poly-lactic-co-glycolic acid (PLGA), polymethyl methacrylate (PMMA), polyethyleneimine (PEI), poly (vinyl alcohol) (PVA), and polyethylene glycol (PEG) [
25,
77,
78]. PLGA is the most commonly used synthetic polymer for microfluidic assembly as a carrier material [
26,
27,
79]. It is a copolymer constituting of PGA (polyglycolic acid) and PLA (polylactic acid) that decomposes into non-toxic byproducts through the Krebs cycle. Besides, by changing the proportions of PGA (hydrophobic compound) and PLA (hydrophilic compound), the degree of hydrophilicity and lipophilicity can be modulated to encapsulate both lipophilic or hydrophilic drugs [
80,
81].
Finasteride, a highly lipophilic compound, was encapsulated in PLGA microspheres using a microfluidic chip containing 7 parallel microchannels (Inventage Lab Inc. Precision Particle Fabrication). PLGA 5050A (acid-terminated with a lactide/glycolide ratio of 50/50) or PLGA 7525A (acid-terminated with a lactide/glycolide ratio of 75/25) were dissolved in dichloromethane (DCM) followed by the addition of finasteride (28 mg) to compose the dispersed phase, while the aqueous solution of PVA (0.25% w/v) was used as the continuous phase [
26,
27]. The dispersed and continuous phases were inserted into the microfluidic chip with a pressure of 1,100 mbar and 2,200 mbar, respectively. Finasteride-added PLGA droplets generated within the channels were polymerized after DC evaporation, lyophilized, and injected subcutaneously into healthy male beagle dogs to assess their drug release and pharmacokinetics
in vivo. The microspheres generated by parallelized microchannels showed high encapsulation efficiency (96.5% - 101.2%) and particle sizes within the recommended range for injectable dosage forms (all smaller than 50 μm). Microspheres produced with PLGA 7502A (75:25 copolymer) exhibited lower initial drug release and more extended-release (about 1 month) in beagle dogs than microspheres based on PLGA 5002A (50:50 copolymer). Besides, the
in vivo drug release profile was proportionally related to the amount of drug loading.
PLGA has also been used to synthesize drug-carrying nanoparticles using the nanoprecipitation method by droplet-based microfluidic approaches [
79,
82,
83]. Nanoparticles are widely studied as potential strategies to improve solubility, bioavailability, circulation time, and delivery efficiency of functional compounds due to their high specific surface area [
84,
85]. Within the microchannels, the formation of polymeric nanoparticles begins when the droplet of the polymer dissolved in an organic solvent has its solubility reduced by mixing the water-miscible organic solvent with an aqueous solution [
79]. However, mixing efficiency may be a limiting factor of using the nanoprecipitation method in microchannels due to the laminar flow regime of the fluids. Staggered herringbone mixers (SHM) are passive mixers inserted into channel walls to destabilize laminar flow and increase mixing efficiency [
86]. Rutin-loaded PLGA nanoparticles were generated in microfluidic devices with SHM using rutin (10 mg/mL) in methanol and PLGA (14.9 mg/mL) in acetonitrile as the dispersed phase (or organic solvent phase) and PVA (1% w/v) as continuous phase (or aqueous phase) [
79]. The optimal formulation of rutin-loaded PLGA nanoparticles prepared by the microfluidics method showed entrapment efficiency of 34 ± 1%, size of 123 ± 4 nm, and drug loading of 0.015 ± 0.001%. Rutin-loaded PLGA nanoparticles produced in the microfluidic devices exhibited a faster release of rutin with higher burst release than those produced in the bulk method. Similar studies applied droplet-based microfluidics using glass and stainless-steel metal devices to obtain nanoparticles of itraconazole and fenofibrate by nanoprecipitation methods. Metal cross-junction channel provided a good mixing environment to generate smaller and more uniform particles of itraconazole, while glass microfluidic devices provided an inert and stable platform for preparing highly monodisperse fenofibrate nanoparticles [
82,
83].
The high manipulating fluids control provided by droplet-based microfluidic devices at the laminar regime allows the design of more elaborate structures using double or multiple emulsions as templates, such as oil-in-water-in-oil (O/W/O) and water-in-oil-in-water (W/O/W) [
37]. For example, a glass capillary microfluidic device with two emulsion generators and one adjusting unit was designed to prepare O/W/O double emulsions [
70]. From O/W/O emulsion templates, alginate core-shell microcapsules were produced by gelling the middle aqueous phase with calcium ions - released from the water-soluble calcium complex after mixing with acidified oil solution (
Figure 3A). Alginate shells had their thickness little affected by alginate concentration and their strength was improved by post-crosslinking in polyetherimide, calcium chloride (CaCl
2), or chitosan solution. The proposed microfluidic approach allowed the precise control of the proportion between different oil droplets (thyme and lavender essential oils) and the number of the oil cores in alginate microcapsules by manipulating flow rates in the microfluidic device [
70]. In another study, a similar glass microfluidic device was manufactured for producing giant unilamellar liposomes from W/O/W emulsions templates using low-cost, food-grade phospholipids (soybean lecithin powder) and FDA-approved toxicological class III solvents (ethyl acetate and pentane) [
87]. Giant unilamellar liposomes are defined as aqueous volumes surrounded by layers of phospholipid molecules. Thus, the oil middle phase consisted of a mixture of soybean lecithin (0.5% w/v) and β-carotene (0.125% w/v) dissolved in different mixtures of organic solvent, while the innermost aqueous phase and the continuous phase contained PVA (1% w/v) mixed with dextran (9% w/v) and only PVA (10% w/v), respectively. After collecting double emulsions, giant liposomes were generated by dewetting and evaporating the organic solvents forming the oil middle phase (
Figure 3B). The giant unilamellar liposomes loaded with β-carotene presented diameters varying between 100 μm and 180 μm, and stability of approximately 7 days. Besides, the presence of β-carotene inside the oil shell did not significantly affect the stability, mean diameter, and coefficient of variation of liposomes compared to those without β-carotene [
87]. Thus, all of the described microfluidic approaches for manufacturing high-performance delivery systems from food-grade emulsions are potentially useful for many applications in the protection, controlled, and sustained delivery of lipophilic functional compounds.
3.2. Hydrophilic functional compounds
Many pharmaceutical, cosmetic, and food industries require delivery systems for hydrophilic functional compounds, including vitamins, enzymes, proteins, bioactive peptides, and drugs. These applications include the need to mask the bitter taste of drugs and minimize their side effects [
88,
89]; improve the bioavailability of functional molecules and control-sustain their release at target sites [
23,
90,
91], flavors and water-soluble colors during storage [
41]. While lipophilic functional compounds can be carried in O/W emulsions, hydrophilic ones are more adequately protected in water-in-oil (W/O) systems. Besides, with the addition of gelling polymers in the dispersed phase, a more efficient protection system can be achieved by gelling the emulsion droplets [
13,
24] .The process of gelling emulsion droplets in microfluidic approaches occurs in two steps. In the emulsification step, the droplet is generated in the microchannels (section 2), followed by the gelation step, which is the solidification of the emulsion droplets induced by a chemical or physical crosslinking agent [
92]. The main gelation methods applied in droplet-based microfluidics (e.g., external, internal, coalescence-induced gelation, and
in situ mixing) differ among them by the location of the biopolymer and crosslinking agent in the different phases and by the triggering mechanism for gelation External and internal gelation are the most popular methods. In the first one, crosslinking agent ions diffuse to the droplet interface from the continuous phase or a bath located outside the channel. In the second, the biopolymer and the crosslinking agent in the inactive form are inserted together into the channel; the release of ions for gelling is triggered by an additional substance dispersed in the continuous phase (
e.g., acetic acid) [
13,
92].
As aforementioned, the 3D network formed by hydrophilic polymers allows the encapsulation of hydrophilic compounds in the polymer matrix. Natural biopolymers derived from animals (
e.g., gelatin and chitosan), plants (
e.g., pectin), algae (
e.g., alginate), and microorganisms (
e.g., gellan gum) have become important carrier materials motivated by their excellent biocompatibility, reproducibility, biodegradability, and ability to form gels easily [
93]. Ogończyk et al., (2011) [
94] produced pectin microgels from W/O emulsions using flow-focusing microfluidic devices. The pectin droplets (0.5 - 1% w/w) were solidified by the external gelation method, in which hydrogen and Ca
2+ were delivered from the continuous phase composed of rapeseed oil, acetic acid (1 - 10% w/w), and calcium carbonate (CaCO
3; 0.05 - 2% w/w). This method allowed the encapsulation of gold nanoparticles in pectin microgels and the control of their release rate. Gellan gum microgels incorporated with
jabuticaba extract, a fruit rich in anthocyanins, were also produced from W/O emulsions by the external gelation method using capillary microfluidic devices [
24]. The emulsions droplets generated by the dripping regime were solidified into gellan microgels induced by Ca
2+ present in the continuous phase (composed of soybean oil, PGPR (4% w/w), and calcium acetate (1% w/w)). However,
jabuticaba extract-loaded gellan microgels (0.2% w/w) showed an irregular structure, a flocculated state with an elliptical shape, and low stability, which was mainly associated with the osmotic pressure difference during the storage and the low gellan gum concentrations. The flow of gellan gum at high concentrations (i.e., high viscosity fluid) into microchannels was a process limitation since Ca
2+ in the
jabuticaba extract triggered gellan gelation, which resulted in an uneasy-flowing material prior to microchannel inlet [
24]. In general, microgels produced from natural polymers have low mechanical performance. However, strategies associated with chemical modification and blending of biopolymers to form hybrid or layer-by-layer hydrogels can overcome this limitation once each polymer's physical and chemical advantages are integrated [
95].
L. Yu et al., (2019) [
96] combined the internal and external gelation methods to control the morphology of the protein-core alginate-shell microgels. In the PDMS microfluidic devices, protein ovalbumin aqueous solution co-flowed with alginate solution (2% w/v) containing CaCO
3 (200 mM) to form a core-shell stream, which was further sheared off by the continuous phase mineral oil containing Span 80 (3% w/w). In general, mineral oil can be safely used in food, and having residue trace amounts would not be a safety concern [
96]. The internal gelation process started with the release of calcium ions from CaCO
3 in the alginate shell due to the insertion of an extra continuous phase composed of mineral oil with Span 80 (3% w/w) and acetic acid (0.2% v/v). The external gelation process was completed in a collecting bath containing CaCl
2 (0.27 M) aqueous solution located outside the device, which ensured the microgels' spherical structure. Furthermore, two approaches were applied to improve the retention of the model protein ovalbumin. In the first one, the alginate microgels were coated with a layer of oppositely charged polymer (poly(ethyleneimine) (PEI) or chitosan). In the second, small particles (inulin microparticles adjuvant) were added inside the water core to block the pores of the polymeric network. The percentage of encapsulation efficiency and protein release of the PEI-coated alginate microgels were 88% e 62% (at 24 h), respectively, while for the chitosan-coated alginate microgels, these values were 80% and 100% (at 48 h), respectively. The highest encapsulation efficiency and sustained-controlled protein delivery were achieved when the two strategies were combined; PEI-coated ovalbumin-delta inulin-encapsulated alginate microgels achieved up to 90% encapsulation efficiency and 20% protein release after 7 days.
Some proteins with intracellular activity have significant potential to treat Crohn's disease and ulcerative colitis [
23]. In these applications, ensuring the protection and controlled-sustained delivery of protein to the specific target is essential, especially for delivering protein therapeutics via the oral route. However, these proteins still need to be internalized into cells and penetrated into natural mucus to exert their therapeutic functions [
23]. Compared to soluble proteins, protein nanoparticles have been shown more capacity to reach inflamed tissue, penetrate the mucosa, and increase cellular internalization [
97,
98]. Using a PDMS microfluidic device, Ling et al., (2019) [
23] produced alginate microgels encapsulating protein (AvrA enzyme) from W/O emulsions by external gelation method. Alginate droplets were gelled in a collecting bath containing CaCl
2 and simultaneously coated with chitosan. Chitosan-coated alginate microgels protected and retained protein activity against harsh gastric conditions
in vitro, whereas its release was induced only in simulated intestinal fluid. In addition, oral administration of protein nanoparticles encapsulated into alginate/chitosan microgels reduced clinical symptoms and histological inflammation scores in a murine dextran sulfate sodium (DSS)-induced colitis pre/co-treatment model.
Encapsulation of multifunctional compounds in oil droplet-templated microgels is also a fascinating strategy for medical and pharmaceutical applications, especially in multidrug treatments with high frequencies of administration [
99]. Mineral oil droplets added with both quercetin nanoparticles and retinyl palmitate were generated inside the PDMS microfluidic devices in an aqueous phase composed of pectin (1 wt%) and Tween 80 (1 wt%). An extra continuous phase composed of water, ethanol (40 wt%), and calcium chloride (1 wt%) was mixed with the O/W emulsion to solidify pectin on the oil droplets' surface based on the pectin's precipitating properties in ethanol and its ionic crosslinking with calcium ions. By changing the flow rate of the phases, the oil core and the shape of the pectin shell were easily controllable. Besides, core-shell microgels could protect quercetin nanoparticles and retinyl palmitate from degradation and oxidation by exposure to water and oxygen [
99].
Similar to lipophilic compounds, the design of more elaborate structures using double emulsions as templates may also be suitable for encapsulating hydrophilic functional compounds [
10,
41,
69,
91,
100]. Pagano et al., (2018) [
41] described the encapsulation of three different sources of betanin, E162 (mixture of beetroot extract and maltodextrin; 0.4% w/w betanin), pure betanin, and spray-dried beetroot juice, in W/O/W emulsions prepared using a straight-through microfluidic device. W/O single emulsions were previously prepared using betanin (0.1 - 1.0% w/w) and D-glucose (1% w/w) as the dispersed aqueous phase, while soybean oil and tetraglycerin monolaurate condensed ricinoleic acid ester emulsifier (CR-310; 1% w/w) were used as the continuous oil phase. These emulsions were inserted into the microfluidic device in a controlled flux (from 5 to 100 L/m
2 h) and broken up into droplets in the outer aqueous phase (aqueous solution of Tween 20, 1 - 3% w/w). Increasing the flux from 5 to 20 L/m
2 h did not affect droplet size. However, droplet size and polydispersity increased when the flux was higher than 100 L/m
2 h. The W/O/W emulsion encapsulating pure betanin showed smaller droplets, higher stability, and droplet size distribution when compared to the emulsions containing betanin from other sources and negative control (without pigment), probably due to the higher electrostatic repulsion observed between these droplets.
While W/O single emulsions are widely used as templates to prepare microgels, O/W/O and W/O/W double emulsions are generally used to fabricate microcapsules (Shah et al., 2008), including solid lipid microcapsules and core-shell microcapsules. Comunian et al., (2014) [
10] used W/O/W emulsions generated into the capillary microfluidic devices as templates to design solid lipid microcapsules (SLMs) loaded with ascorbic acid. SLMs consist of a matrix made of solid lipids stabilized in an aqueous dispersion by surfactants or polymers [
101]. Thus, melted palm fat was used as the middle phase, while the innermost aqueous phase and the continuous phase contained ascorbic acid solution (3 - 20% w/w) with or without the presence of salt (Na
2CO
3) or/and chitosan (0.25% w/w) and only PVA (10% w/v), respectively. The W/O/W emulsion was collected in an ice bath to rapidly solidify the oil droplets to form a shell. The encapsulation efficiency of ascorbic acid increased from 73% to about 90% when salt and chitosan were added to the SLMs. Two different mechanisms to increase ascorbic acid's encapsulation efficiency and stability were described: (1) the clogging of the pores generated during the lipid solidification process at high salt concentrations and (2) the presence of chitosan inside the core, acting with a micromolecule-chelating agent (
Figure 4) [
10].
Although many studies point to core-shell microcapsules as candidates for drug delivery systems, most of the materials used for producing these systems by microfluidic techniques are synthetic polymers, including food-grade ones (
e.g., PLGA) [
69,
91,
100,
102]. PLGA microcapsules encapsulating mesoporous silica nanoparticles (MSNs) were generated from W/O/W emulsion via capillary microfluidic devices to obtain further, more specific control over drug release kinetics. MSNs can penetrate tissues through capillaries and be absorbed by cells, improving drug delivery to injury sites in the body. To generate W/O/W emulsions in microchannels, the innermost aqueous phase was composed of MSN solution, while PLGA solution (0.6 wt% in DCM) was injected into the microchannel as the middle oil phase. The PVA aqueous solution (outermost phase) flows through the square capillary from the opposite direction of the inner and middle phases. After double emulsion generation, the PLGA microcapsules were solidified by the evaporation of DCM. The mean diameter of MSNs-loaded PLGA microcapsules was 56 μm (CV= 4.91%). Furthermore, the release of a model dye from these microcapsules was sustained for 4 months without any observable burst release [
91].
H. Chen et al., (2018) [
100] used the same microfluidic approach to produce PLGA microcapsules loaded with 2-[[(4-phenoxyphenyl)sulfonyl]methyl]-thiirane (SB-3CT) for traumatic-brain-injury (TBI) pharmacological therapy. The PLGA-SB-3CT microcapsules with sizes ranging from 35 to 65 µm and encapsulation efficiency of 99% presented an SB-3CT releasing duration of around 50 days. Then, PLGA-SB-3CT microcapsules injected in rats at the trauma site after TBI showed preliminary neuronal protection efficacy by accelerating behavioral recovery and reducing neuronal cell apoptosis in CA2, hilus hippocampus, and cortical injury region. In another study, core-shell microparticles were produced from W/O/W emulsion templates using gelatin-methacryloyl (GelMa) as the core and PLGA oil solution as the shell for synergistic and sustained drug delivery applications [
102]. GelMa is a semi-synthetic material obtained from the reaction of gelatin with methacrylic anhydride, which results in the modification of hydroxyl and lysine residues with methacrylate and methacrylamide side groups [
103]. The GelMa core added with doxorubicin hydrochloride (DOX, hydrophilic drug) was photopolymerized under UV illumination downstream from the capillary microfluidic channel, while the PLGA shell added with camptothecine (CPT, hydrophobic drug) was solidified after DCM evaporation. Drug release from core-shell microcapsules initially occurred by diffusion of DOX from the GelMa core and delivery of DOX and CPT to the external environment through pores throughout the PLGA shell. With the degradation of the PLGA shell, the DOX and CPT drugs were also gradually released. Furthermore, liver cancer cells (HCT116 and HepG2) treated with GelMa-PLGA core-shell microcapsules loaded with DOX and CPT showed reduced viability (less than 20% for HCT116 cells and 10% for HepG2 cells), which confirmed the high therapeutic efficacy of these microcapsules in treating liver cancer cells [
102].
Table S2 summarizes the technological approaches and properties of the delivery systems based on food-grade emulsions assembled by microfluidic techniques, including microfluidic device type, emulsification process conditions, functional compound type, and delivery system characteristics (
e.g., size, polydispersity, and encapsulation efficiency). Other recent studies have also pointed to microfluidics as an excellent tool for obtaining delivery systems based on food-grade emulsions. In general, these works aimed to evaluate droplet formation process parameters using complex fluids and/or the development of new geometries or microfluidic devices without effective encapsulation of a functional compound. Considering their technological potential to act as delivery systems,
Table S3 presents the most recent droplet-based microfluidics approaches to obtain emulsified systems, including the phase compositions, emulsification process conditions, and microfluidic device type.